Search Results for "reactive"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for reactive. Results 91 to 100 of 112 total matches.

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
warning about a risk of hepatitis B virus reactivation associated with their use8; hepatitis B surface ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Mercury in Fish

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009  (Issue 1327)
consumption and markers of cardiovascular risk (e.g., C-reactive protein and high density lipoprotein ...
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in seafood is in the form of methylmercury, a potential neurotoxin formed by the organification of elemental mercury by marine microorganisms like plankton, which are then consumed by aquatic animals and concentrated up the food chain.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):103-4 |  Show IntroductionHide Introduction

Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
reactivation and emergence of drug resistance. Summary: Cabotegravir/Rilpivirine (Cabenuva) An extended ...
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, as a once-monthly complete regimen for intramuscular (IM) treatment of adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA...
Med Lett Drugs Ther. 2021 May 31;63(1625):81-3 |  Show IntroductionHide Introduction

Drugs for Smoking Cessation

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
decreased cell viability, increased levels of reactive oxygen species, and other markers of endothelial ...
Smoking tobacco remains the primary preventable cause of death in the US. Smoking cessation often requires both pharmacotherapy and behavioral support.
Med Lett Drugs Ther. 2019 Jul 15;61(1576):105-10 |  Show IntroductionHide Introduction

Natalizumab (Tysabri) for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005  (Issue 1202)
it with azathioprine for Crohn’s disease. PML is an opportunistic infection of the brain, caused by reactivation ...
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Med Lett Drugs Ther. 2005 Feb 14;47(1202):13-5 |  Show IntroductionHide Introduction

Thiazolidinediones and Cardiovascular Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007  (Issue 1265)
-reactive protein and carotid intima-media thickness. 5,6 Pioglitazone has a more favorable lipid ...
The thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) are peripheral insulin sensitizing agents used to treat hyperglycemia in patients with type 2 diabetes; one or the other is often used as a second or third agent with metformin (Glucophage, and others) and/or a sulfonylurea such as glimepiride (Amaryl, and others). A recent report suggested that rosiglitazone may increase the incidence of myocardial infarction (MI) and cardiovascular mortality.
Med Lett Drugs Ther. 2007 Jul 16;49(1265):57-8 |  Show IntroductionHide Introduction

Ocrelizumab (Ocrevus) for MS

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017  (Issue 1523)
reactivation, hepatic failure, and death; ocrelizumab is contraindicated for use in patients with active HBV ...
The FDA has approved ocrelizumab (Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Med Lett Drugs Ther. 2017 Jun 19;59(1523):98-101 |  Show IntroductionHide Introduction

Expanded Table: Some Vaccines for Travelers (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
, and reactive arthropathy have been reported Yellow Fever YF-Vax (Sanofi Pasteur)15 0.5 mL SC (4.74 log10 ...
View the Expanded Table: Some Vaccines for Travelers
Med Lett Drugs Ther. 2018 Nov 19;60(1560):e192-4 |  Show IntroductionHide Introduction

Drugs for Stable Angina Pectoris

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 1994  (Issue 937)
cardioselective beta-blockers can produce severe bronchospasm in patients with asthma or other reactive airway ...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
acetylcholinesterase reactivator that binds to the nerve agent, removing it from its binding site and reversing muscle ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction